Validation of the vesicular acetylcholine transporter (VAChT) and the neuronal vesicular monoamine transporter (VMAT2) as important molecular targets in the cholinergic and dopamine neurons, respectively, has sparked interest in the development of radiotracers for studying these markers in vitro and in vivo. Currently, a number of selective high-affinity radiotracers are available for studying these targets in vivo with positron emission tomography (PET) or single photon emission computed tomography (SPECT). PET studies of VMAT2 in neuropathology reveal changes in the density of this marker that can be verified independently. Similarly, in vivo studies with VAChT ligands suggest that the latter are potentially useful in detecting cholinergic lesions in vivo; however, additional development is required to fully realize the potential of these radioligands.-Efange, S. M. N. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J. 14,
The specific interaction between a biologically active molecule (termed the ligand) and its molecular target or receptor can trigger a myriad of biological responses, and the blockade of this interaction can also result in dramatic consequences. Ligand-receptor interaction is therefore recognized as critical to information transfer in the living organism, and thus essential for the continued viability of the organism. Radiotracer methodology provides a powerful tool for studying ligand-receptor interactions. However, when used in vitro, this technique lacks a dynamic component as one is limited to examining tissue samples. When combined with in vivo imaging techniques, the radiotracer method becomes an immensely powerful tool for studying living biological systems under a variety of conditions, normal, pathological and experimentally induced. Currently, in vivo radiotracer imaging uses two major techniques: positron emission tomography (PET) and single photon emission computed tomography (SPECT) (1, 2) . Basically, PET differs from SPECT in that the former uses coincidence detection to capture the signal emitted by the annihilation of a positron, as the two resulting annihilation photons diverge at 180°relative to each other. Traditionally, the coincidence detection technique has provided higher spatial resolution for PET; however, recent advances in SPECT technology have narrowed the gap between the two technologies. In both SPECT and PET, the desired radioligand is synthesized by introduction of a selected radionuclide into a precursor molecule. For PET scanning, the radionuclides carbon-11, nitrogen-13, and fluorine-18 are commonly used. The most common radionuclides used in SPECT are iodine-123 and technetium-99m. In vivo validation of radioligands generally takes the form of biodistribution and radioligand blocking studies, kinetic and metabolite analysis. In the biodistribution study, the distribution of the tracer in the organ of interest is examined over time and compared with the distribution of the molecular target determined by independent methods. To facilitate data analysis, regions of low or insignificant target density are generally used as reference regions, which explains the frequent reference to parameters such as the striatum:cerebellum and striatum:cortex ratios in this review. Blocking studies are used to show that the radioligand binds to the site in question, whereas the kinetic assessment is used to adequately describe the in vivo behavior of the ligand. A major shortcoming of the radiotracer methodology is its inability to distinguish between chemical species bearing identical radionuclides. Radiotracer metabolism is therefore an important consideration in the study of living systems with PET or SPECT.
The current review focuses on the development of radioligands and in vivo imaging of the vesicular 1 Correspondence: Department of Radiology (Mayo Box 292), University of Minnesota. Academic Health Center, 420 Delaware St. SE, Minneapolis, MN 55455, USA. E-mail: efang001@maroon.tc.umn.edu acetylcholine transporter (VAChT) and vesicular monoamine transporter (VMAT). Although the main thrust of the review is in vivo imaging, a portion of the discussion is devoted to ligand development and studies performed with 125 I-and tritium-labeled ligands because the latter provide the foundation on which in vivo investigations are built. Because the results of an imaging experiment can be profoundly influenced by the radiotracer used, the author chose to review the available in vivo data with reference to specific radiotracers. This arrangement provides the reader with a better appreciation of developments in the area and a grasp of controversial issues and their origins.
PROGRESS IN THE DESIGN, SYNTHESIS, AND PHARMACOLOGICAL CHARACTERIZATION OF VAChT LIGANDS

Vesamicol: molecular beacon for a cholinergic marker
Interest in the simple lipophilic aminoalcohol 2-(4-phenylpiperidinyl)cyclohexanol (AH5183, vesamicol) can be traced to the discovery that the latter, originally synthesized as a potential local anesthetic, displays neuromuscular blocking properties that are similar to those of (ϩ)-tubocurarine but are of prejunctional origin (3, 4 12) . ACh accumulation and vesamicol binding are expressed by a single polypeptide, suggesting that all of the essential components of the VAChT reside in that polypeptide. Thus, the terms vesamicol receptor (VR) and VAChT are synonymous. The gene for VAChT is embedded within the first intron of the gene for ChAT in all of the species examined, suggesting that the expression of ChAT is tightly coupled to that of VAChT (11, 13, 14) . In several studies of the rat brain, staining for VAChT protein, vacht mRNA, ChAT protein, and chat mRNA has unequivocally revealed that VAChT is localized to synaptic vesicles within cholinergic terminals (11, 13, 14 -19) . In fact, VAChT has been used to confirm certain aspects of the cholinergic system whose existence had been a subject of controversy. Consequently, VAChT is now firmly established as a reliable cholinergic marker. This review summarizes the development of VAChT ligands for in vivo imaging in the past decade.
Although the distribution of (Ϫ) 
IN VIVO IMAGING OF VAChT Primate studies (ϩ)-[ 123 I]MIBT
Only one imaging study (30) ]MIBT was administered in a female baboon by i.v. bolus, followed by constant infusion over 6 -7 h. Stable levels of radioactivity were observed in the striatum, occipital cortex, and cerebellum after 3 h. Injection of pentazocine at 4 h postinjection induced a dose-dependent decline of radioactivity in the occipital cortex and cerebellum, suggesting contribution from receptors. The striatum was unaffected by this treatment. These observations agree with earlier findings in the rat; however, they are clearly at variance with studies of (ϩ)- 
(ϩ)-[ 18 F]FBT
A number of PET studies have used this radioligand. In one study (31) of young adult rhesus monkeys, (ϩ)-[ 18 F]FBT was found to bind reversibly and to distribute heterogeneously in the brain. Clearance of the radiotracer was slow in the basal ganglia relative to the cortex and cerebellum, resulting in a progressive increase in the striatum:cerebellum ratio. At 180 min after radiotracer injection, the value of this ratio approached 2. Although the cerebral cortex contains a much higher density of cholinergic terminals than the cerebellum, comparable levels of the radiotracer were observed in both structures throughout the duration of the study. Since (ϩ)-FBT displays 100-fold higher affinity for VAChT than for 1 and 2 receptors, the authors concluded that the poor signal:noise ratio obtained from the cortex was not due to receptors but to one or more of the following factors: the low density of cholinergic terminals in the primate cortex, partial volume averaging caused by the low spatial resolution of the PET scanner, or the relatively high lipophilicity of (ϩ)-[ . However, the decrease was not observed in every aged subject. Indeed, whereas some aged subjects displayed significant reductions in (ϩ)-[ 18 F]FBT accumulation, others were found to accumulate the radiotracer at levels comparable to those observed in young adults (Fig. 2) . This observation led the authors to conclude that the susceptibility of the cholinergic system to the aging process is subject to individual variation. Future studies that link the decline in (ϩ)- may provide further insight into the utility of this agent. 
Human studies (Ϫ)-[ 18 F]NEFA
Only one PET study (36) has been reported for this radioligand. The study used three subjects aged 60 -65 years; two were controls and one suffered from AD. As previously observed in cynomolgus monkeys, high levels of radiotracer were observed in the striata of the healthy subjects. The striatal concentration remained constant for the duration of the study (60 min). However, the authors could find no demonstrable binding of radiotracer in the human cortex. Similar results were obtained from the single AD subject. To explain the poor retention of (Ϫ)- [ 18 F]NEFA in the human cortex, the authors suggest that the kinetics of this radiotracer in the striatum are different from those of the cortex. This claim is supported by the finding that in rat brain slices, 
The cholinergic reserve strategy
Since the discovery that vesamicol is a high-affinity ligand, new VAChT ligands have been routinely screened for site binding. In some of the earlier studies of radiolabeled vesamicol analogs, investigators observed that the accumulation of radiolabeled VAChT ligands within the mammalian striatum was enhanced by pretreatment with the sigma ligand (and dopamine antagonist) haloperidol. Upon further investigation, the seemingly paradoxical enhancement was found to be mediated by blockade of striatal dopamine D2 receptors. Dopaminergic control of striatal cholinergic neurons is exerted via D2 receptors found on these neurons. Blockade of these receptors results in disinhibition of striatal cholinergic activity that manifests as an increase in the release of ACh (39, 40) , probably via the recruitment of synaptic vesicles from a reserve pool into an active pool. Since the enhanced accumulation of radiolabeled VAChT ligands appeared to parallel the facilitated release of ACh in the striatum, Ingvar et al. (35) suggested that the binding of VAChT ligands is sensitive to the level of striatal cholinergic activity. Further investigation of this link has led to the development of a pharmacologic activation strategy for in vivo VAChT imaging that is similar to the 'stress test' used routinely in nuclear cardiology. Within the context of this strategy, striatal cholinergic activity is presumed to vary between a basal and maximum level. Between these two extremes exists a dynamic range that reflects the functional reserve of the cholinergic system. To determine the magnitude of this reserve, striatal cholinergic neurons are exposed to a dopamine D2 antagonist to increase their level of activity. The increased cholinergic activity is then measured as enhanced accumulation of a radiolabeled VAChT ligand within the striatum. A key underlying assumption of this method is that the extent of dopamine antagonist-mediated enhancement in cholinergic activity is proportional to the cholinergic reserve. While the technique is currently undergoing extensive investigation in nonhuman primates, preliminary studies in rodents suggest that the cholinergic reserve as measured by radiolabeled VAChT ligands declines with aging (27) and after destruction of the nigrostriatal dopaminergic pathway (26) . Because pharmacological activation may provide important clues regarding tissue/organ function, the cholinergic reserve may yet prove to have important correlates in central cholinergic function.
DISCORDANCE BETWEEN VAChT and ChAT IN CENTRAL CHOLINERGIC DYSFUNCTION: REAL OR IMAGINED?
Reduced basocortical innervation is a hallmark of Alzheimer's disease. In addition, the depletion of the cholinergic markers ChAT and AChE is correlated with the severity of the disease (41. 42) . Reduced cholinergic function is also associated with other neurological disorders, including Parkinson's disease with dementia (43), olivopontocerebellar atrophy (OPCA) (44) , and amyotrophic lateral sclerosis (45) . A putative cholinergic marker would therefore be expected to show the appropriate changes when examined in these disorders and/or in animal models thereof. Because ChAT is generally regarded as the gold standard for cholinergic markers and because of the unique anatomic and functional arrangement of the cholinergic gene locus, changes in VAChT expression in disease states have invariably been compared with corresponding alterations in ChAT. Coordinate expression of VAChT and ChAT has been observed in the sympathetic superior cervical ganglion (46) , in cultured sympathetic neurons (47) , and in a murine septal cell line (48) after treatment with cytokines or neurotrophic factors. VAChT and ChAT also appear to be coordinately expressed after experimentally induced injury. Matsuura et al. (49) report that after unilateral transsection of the hypoglossal nerve in adult rats, the levels of vacht and chat mRNA were dramatically reduced within 1 wk. Thereafter, the expression of both markers recovered slowly. Gilmor et al. (50) report similar observations after either axotomy or immunotoxin-induced lesions of the rodent septohippocampal pathway. Finally, maternal exposure to lead also results in a decline in the expression of both cholinergic markers (51) . Coordinate expression of VAChT and ChAT appears to extend to idiopathic neuropathology as revealed by a recent report. In postmortem human brain tissue, Gilmor et al. (52) found that the decrease in the number of VAChT-and ChAT-immunopositive neurons in the nucleus basalis highly correlates with the severity of dementia. In an examination of subjects with no cognitive impairment, mild cognitive impairment, and early-stage AD, there were no significant reductions in either marker, suggesting that VAChT and ChAT are preserved in early AD. The tight functional link between the two markers thus appears to survive the early stages of AD.
If coordinate regulation is the norm at the cholinergic locus, what then is the source of the disparity between ChAT and VAChT in human neurological disorders and in animal models? [We note here that the disparity in question is that observed between ChAT enzyme activity and VAChT density as measured by radioligands.] As indicated previously, ear-lier workers had attributed the disparity to one or more factors, including compensatory mechanisms and poor radioligand selectivity. Since those studies predate our current knowledge of VAChT and the cholinergic locus, a re-examination of the explanations advanced by these workers appears to be warranted at this time: (30, 31, 53) , the loss of selectivity becomes particularly evident in brain regions, such as cortex, containing a high density of binding sites.
Cholinergic neurons that survive the lesion may compensate by expressing higher levels of synaptic vesicles (and concomitantly higher levels of VAChT).
Evidence from rapid autopsy material collected from patients with Alzheimer's disease suggests that surviving cholinergic terminals in the cortex display marked hyperactivity (54), suggesting compensatory up-regulation. Although the increase in cholinergic activity was inferred from increased sodium-dependent, high-affinity choline uptake, it is reasonable to expect that both ChAT and VAChT would also be up-regulated under these conditions in order to sustain the heightened level of cholinergic activity. The latter view is consistent with the available evidence, which strongly suggests that the tight functional link between ChAT and VAChT is maintained in both normal and pathological conditions. Consequently, without some evidence of functional decoupling between ChAT and VAChT, one can find little support for the above claim at this time.
3. One segment of surviving cholinergic terminals may express inadequate levels of ChAT and AChE. Previous studies (55, 56) have suggested that the extent of reduction of ChAT in the cerebral cortex exceeds the magnitude of neuronal loss in the nucleus basalis. However, VAChT levels were not measured in these studies. As a result, this claim remains largely unverified.
4. Degenerating (ChAT-deficient) cholinergic terminals may exhibit up-regulation of VAChT. Although the majority of studies suggest that VAChT and ChAT are coordinately regulated under normal conditions and in neuropathology, at least one study (57) has provided evidence of differential regulation of these markers during development. Consequently, one cannot completely discount the possibility that such functional decoupling also occurs in certain phases of the neuropathology.
Given the high affinity of vesamicol for binding sites (and its marginal selectivity for VAChT), it now appears that the failure of this ligand to detect reductions in VAChT density is largely due to competition from binding sites. This view is supported by the observation that the extent of the mismatch between ChAT activity and VAChT density varies with both the nature of the VAChT ligand and the brain region examined. Thus, with more selective VAChT ligands, the mismatch between ChAT and VAChT appears to be smaller (vide supra). However, the discrepancy between these reliable cholinergic two markers has not been completely eliminated. Therefore, additional investigation is clearly indicated.
Since the discovery of vesamicol, several analogs have been synthesized and characterized. One of the analogs, 4-aminobenzovesamicol (or ABV), is the most potent VAChT ligand (K i ϭ 6.5Ϯ0.5 pM) known (58) . The compound is significantly more potent (58) and selective than vesamicol (23) . Because the high affinity of (Ϫ)- 
THE VESICULAR MONOAMINE TRANSPORTER Background
Adrenal chromaffin granules store and release catecholamines into the bloodstream. Analogous structures for monoamine storage in neurons and platelets are called vesicles. Specific uptake of catecholamines by chromaffin granules and other vesicles has been recognized for years. This transport system is mediated by a membrane protein named the vesicular monoamine transporter, or VMAT. As the name implies, the transporter displays limited substrate specificity, accumulating catecholamines, serotonin and tyramine. Molecular cloning experiments have revealed the existence of two isoforms of VMAT, named VMAT1 and VMAT2, that arise from different genes (reviewed in ref 59). Whereas VMAT1 is localized in chromaffin granules, VMAT2 is found almost exclusively in neurons. The two forms of VMAT are also distinguished by their sensitivity to inhibitors; thus, reserpine inhibits the function of VMAT1 and VMAT2 with comparable potency, whereas tetrabenazine (TBZ) exhibits 10-fold greater potency for VMAT2 over VMAT1. Reserpine and tetrabenazine are the most selective inhibitors of vesicular monoamine transport. As a result, these two compounds have provided the starting point for the development of radioligands for studying VMAT both in vitro and in vivo. This review focuses on tetrabenazine and its analogs (Fig. 3) , as little work has been done on reserpine analogs as radiotracers for in vivo imaging. An earlier review (60) of radiotracers for the in vivo imaging of VMAT2 has been published.
Radioligands for studying VMAT
TBZOH is one of the major metabolites of TBZ. Like the parent, TBZOH is a potent inhibitor of VMAT2. In the rat, specific binding of [ 3 H]TBZOH appears to be unaffected by medium-term treatment with a number of pharmacologic agents that influence dopaminergic neurotransmission (62) . This led to the conclusion that reliable measures of VMAT2 density may be obtained from subjects undergoing long-term pharmacotherapy with these agents. However, in ovariectomized rats, treatment with progesterone for 21 days resulted in a reduction in [ 3 H]TBZOH binding in the striatum and nucleus accumbens that was matched by a decline in VMAT2 mRNA expression in the substantia nigra pars compacta and dorsal raphe nuclei (63) . Estradiol treatment had similar effects on [ 3 H]TBZOH binding.
However, with estradiol VMAT mRNA expression was altered only in the nucleus accumbens. VMAT2 density may thus be affected by some pharmacologic treatments. Pharmacological characterization of [ 3 H]TBZOH binding (64) in the human brain postmortem revealed a single class of high-affinity sites (K d ϭ7 nM). The distribution of [ 3 H]TBZOH binding sites was heterogeneous in the mesencephalon of control subjects and consistent with the distribution obtained from tyrosine hydroxylase immunohistochemistry. The highest densities of [ 3 H]TBZOH binding were observed in the substantia nigra pars compacta, locus coeruleus, and dorsal raphe nucleus. Moderate and low densities were found in the ventral tegmental area and substantia nigra par reticulata, respectively. In Parkinsonian subjects, [ 3 H]TBZOH binding declined drastically in all regions examined except in the substantia nigra pars reticulata, thereby supporting the use of radiolabeled TBZOH for in vivo imaging. [
2-[
11 C]TBZ was converted principally to ␣-and ␤-[ 11 C]dihydrotetrabenazine. At 15 min postinjection, these metabolites accounted for up to 57% of the total radioactivity in the blood. Imaging experiments in the monkey revealed a similar pattern of tracer distribution. After MPTP-induced unilateral lesion of the nigrostriatal pathway, [ 11 C]TBZ binding in the ipsilateral striatum was abolished; radiotracer accumulation in the contralateral striatum and cerebral cortex was unaffected (67) . Therefore, [
11 C]TBZ appears to be a suitable tracer for studying central nervous system (CNS) disorders characterized by changes in monoaminergic terminal density. Data analysis may, however, be complicated by the presence of the metabolite ␣-[ In preliminary studies in mice, [ 11 C] MTBZ displayed a distribution profile similar to that described for [
11 C]TBZ. The specific binding of [ 11 C]MTBZ in rat brain sections was blocked by reserpine, but was unaffected by dopamine, bromocriptine, N-methylspiperone, haloperidol, nomifensine, L-deprenyl, and desipramine (68) . After unilateral 6-OHDAinduced lesion of the median forebrain bundle, specific binding of [ 11 C]MTBZ declined by 62% in the ipsilateral striatum, whereas the contralateral striatum was unaffected. The unilateral reduction in [
11 C]MTBZ binding was highly correlated with the loss of tyrosine hydroxylase-positive cells in the substantia nigra pars compacta (68) .
To further validate the use of this radiotracer for studying CNS disorders associated with changes in monoaminergic terminals, Kilbourn et al. (69) evaluated this tracer in the tottering mouse, a model of generalized epilepsy. Fluorescence histochemistry measurements of monoamine levels in this model have previously revealed two-to threefold increases in norepinephrine levels in striatum, hippocampus, and cerebellar cortex, and a moderate increase of this neurotransmitter in the occipital cortex, relative to control animals. Dopamine levels in striatum appear to be unchanged. In all brain regions examined, [ 11 C]MTBZ concentrations were increased significantly relative to controls and correlated highly with independently determined measures of norepinephrine. [ 11 C]MTBZ binding is thus sensitive to both reductions and increases in monoaminergic innervation.
The distribution of [ 11 C]MTBZ has also been evaluated in normal human volunteers (70) . Rapid tracer accumulation in the brain is quickly followed by clearance from all brain regions. Tracer efflux is slowest in regions of high VMAT density. As a result, regions such as the caudate and putamen are clearly distinguished from the cerebellum 45 min after radiotracer injection. Consideration of kinetic parameters obtained from a 2-compartment model also suggests that [ 11 (71, 72) . With the infusion method, total and specific distribution volumes correlated well with the specific distribution of VMAT2 determined by in vitro methods. With the bolus method, regional estimates of radiotracer density also correlated highly with in vitro values. However, in regions of high radiotracer density, this mode of administration tends to overestimate VMAT2 density by 10 -15%. A subsequent study concluded that excellent estimates of VMAT2 can be obtained by a simple protocol that combines a loading bolus injection, followed by continuous infusion. Detailed kinetic analysis of dynamic PET data suggests that with a 3-compartment model [ 11 C]TBZOH can provide excellent measures of VMAT2 density in the human brain from a single PET study (73) . Other investigators have confirmed that PET imaging with [ 11 C]TBZOH can provide reproducible in vivo measurements of VMAT density (74) . However, these authors find that the cortex serves as a more reliable reference region than the cerebellum. Since neither region is completely devoid of monoaminergic terminals, data analysis must proceed with caution no matter which of the two regions is used as reference.
In vivo Imaging of VMAT in neuropathology
PET imaging with [ 11 C]TBZOH has been used to assess the status of monoaminergic innervation in a number of neurological/neuropsychiatric disorders.
Immunochemical analysis of VMAT2 protein density in postmortem human tissue reveals marked reductions in the caudate and putamen in PD (75) . The distribution of VMAT parallels that of the plasma membrane dopamine transporter (DAT) in normal subjects. Moreover, reductions in VMAT2 density parallel those observed for DAT, a phenotypic marker of dopaminergic neurons. PET imaging with [ 11 C]TBZOH confirms the decline in nigrostriatal dopaminergic innervation (76) . In this study, the authors found that the specific binding of (77) . In this study, seven severely alcoholic men without WernickeKorsakoff disease were compared with an equal number of male control males of similar ages. Both the blood-to-brain transfer rate and the specific binding of [ 11 C]TBZOH were reduced in the caudate and putamen; however, the reductions in these two parameters only reached significance in the putamen. Therefore, PET scanning with [ 11 C]TBZOH suggests measurable damage to striatal monoaminergic terminals in severe chronic alcoholism.
In multiple system atrophy (MSA), recent studies with [ 11 C]TBZOH suggest neurochemical correlates for different forms of the disease (78, 79) . In a study comparing normal controls with subjects afflicted with MSA, specific [ 11 C]TBZOH binding declined by 61 and 58% in the caudate and putamen, respectively. When the same controls were compared with subjects afflicted with sporadic OPCA, specific radiotracer binding in the caudate and putamen were reduced by only 26 and 24%, respectively. A subsequent PET study with [ 11 C]TBZOH (79) compared 7 normal control subjects with sporadic OPCA patients, and patients diagnosed with MSA characterized by 1) predominantly Parkinsonian features (MSA-P) and 2) principally cerebellar dysfunction (MSA-C). The authors report a reduction in mean blood-to-brain transfer rate in the putamen of all three patient groups and in the cerebellar hemispheres of the MSA-C and sOPCA groups. No change was observed in the cerebellar hemispheres of the MSA-P group. Moreover, a significant negative correlation was observed between striatal tracer accumulation and the severity of Parkinsonism. Similarly, the cerebellar blood-to-brain transfer rate was negatively correlated with the intensity of cerebellar dysfunction.
Expression of VMAT2 and DAT is highly correlated in the normal brain. However, preliminary studies with [ 11 C]TBZOH suggest that this concordance is lost after chronic cocaine use (80) . In a postmortem study of 15 chronic cocaine users and an equal number of matched controls, the authors found that striatal DAT binding sites were increased significantly with chronic cocaine use. Moreover, the increase in DAT was correlated with the severity of cocaine use. In contrast, VMAT2 density (measured  with [ 3 H]TBZOH) declined slightly (ϳ11%). Postmortem studies of human cocaine overdose victims have examined VMAT2 expression with a combination of radioligand ([   125   I ]IV-TBZOH) binding and immunoautoradiographic techniques (81) . Quantitative autoradiography failed to show significant differences in VMAT2 density between control and cocaine overdose victims. Similar results were obtained from the immunocytochemical technique. Previous studies in the rat have shown that VMAT2 density is unaffected by chronic cocaine use (82) . Dysregulation of DAT and VMAT2 may therefore be characteristic of neuropathology. Indeed, such dysregulation may also underlie the discordance between DAT density and [ 11 C]TBZOH binding observed in Tourette's syndrome (83) .
Given the apparent sensitivity of [ 11 C]TBZOH to changes in VMAT2 density, it is reasonable to conclude that the latter offers promise as a clinical tool for diagnosis of neurological disorders associated with changes in monoaminergic innervation.
SUMMARY
Independent demonstrations of discrete disease-related changes in the densities of vesicular amine transporters suggest a role for techniques, such as the radiotracer method, that can detect such changes in vivo. For VMAT, radiotracer development, a critical step for in vivo imaging with PET or SPECT, has proceeded smoothly. [
C]TBZOH and [
11 C]MTBZ have been used successfully with PET to detect changes in VMAT2 density in neuropathology. For VAChT, the radiotracer development effort has been even more extensive, largely because the lead structure vesamicol contains critical recognition elements that are common to both VAChT and the 1 and 2 receptors. From these studies, numerous potent and highly selective VAChT ligands have been developed. Though these appear to show promise in the detection of cholinergic lesions in vivo, data interpretation has been complicated by a recurring mismatch between measurements of VAChT density and ChAT activity. Since VAChT has been clearly established as a reliable cholinergic marker, the mismatch does not question the validity of VAChT as a target. The apparent discordance between the two cholinergic markers does, however, calls for additional investigations that are aimed at validating newly developed tracers and their method of use.
